March 2026
Learning Objectives
Upon completion of the educational activity, participants should be able to:
- Improved understanding of subtype-specific immune mechanisms and the role of autoantibodies in disease course and management.
- Greater familiarity with evidence supporting new and emerging therapies; increased confidence in selecting appropriate patients for these treatments.
- Increased recognition of diagnostic delays, treatment toxicity, and gaps in addressing patient-reported outcomes.
Activity Disclosures
This activity is supported by an educational grant from Argenx.
Disclaimer
Dr Victoria Werth: Consulting: Lilly, Pfizer, Biogen, BMS, Gilead, Amgen, EMD Sorona, CSL Behring, Crisalis, Argenx, Kwoya Kirin, Regeneron,AstraZeneca, Abbvie, GSK, UCB, Merck, Sanofi, Cabaletta Bio, Nuvig Pharmaceuticals, Takeda Pharmaceuticals, Immunovant, Anaptysbio, Evommune, Innovaderm, Boehringer Ingelheim Pharmaceuticals, Quotient Therapeutics, Duality Biologics, Glycoera, Almirall, Atticus,Inmagene, Exo, Novartis, Xencor, Architect Therapeutics, Celexor, Bimmunity
Grants: Pfizer, Biogen, Gilead, Corbus Pharmaceuticals, AstraZeneca, Amgen, Regeneron, CSL Behring, Horizon, Priovant, Ventus, Viela,Glycoera, Chugai
University of Pennsylvania owns the copyright for the CLASI and CDASI and DMOMS and IGA-DM and IGA-CLE
Dr Tahseen Mozaffar: Advisory roles: Alexion (Astra-Zeneca), Amicus, AnnJi, Argenx, Aro Bio, Ask-Bio, Audentes (now Astellas Gene Therapy), CreyonBio, Fate Therapeutics, Maze Therapeutics, Momenta (now Janssen), Regeneron, Sanofi, Shionogi, Spark Therapeutics, UCB/RaPharmaceuticals, Modis/Zogenix (now UCB), Variant Bio;
Speakers Bureau: Sanofi-Genzyme
Medical Advisory Board: The Myositis Association, Neuromuscular Disease Foundation.
Research Funding: NIH, NCATS, TMA, Alexion, Amicus, AnnJi, Argenx, Ask Bio, Audentes/Astellas Gene Therapy, Aro Bio, Cabaletta, CartesianTherapeutics, Fate Therapeutics, ML-Bio, NKarta, Sanofi, Shionogi, Spark Therapeutics, UCB, and Ultragenyx.
Data Safety and Monitoring Boards: Applied Therapeutics, Sarepta, Sirolimus in IBM, and the NIH.
Dr Rohit Aggarwal: Research grants: Boehringer Ingelheim (BI), Cabaletta Bio, Janssen, and PRoivant.
Consulting: Abcuro, Alexion, ANI Pharmaceutical, Argenx, Artiva Biotherapeutics, AstraZeneca, Boehringer Ingelheim, Bristol Myers-Squibb,Cabaletta Bio, Capstanx, Century Therapeutics, CSL Behring, Dren Bio, EMD Serono, Fate Therapeutics Inc, Galapagos, GlaxoSmithKline LLC(GSK), Horizontal Therapeutics, Immunovant, Janssen, Janux Therapeutics, Kiniksa Pharmaceuticals, Lilly, Meiji Pharma,Novartis, Nkarta, Octapharma, OneFour Bio, Orna Therapeutics Inc, Ouro Medicines, Pfizer, PRoivant, SOBI, and Sun Pharmaceutical Industries.
This activity underwent review in line with standards of editorial integrity and publication ethics. Potential conflicts of interest have been identified and resolved in accordance with John Wiley and Sons, Inc.’s Policy on Activity Disclosure and Conflict of Interest. The primary resolution method was review by an unconflicted expert. For information about the accreditation of this program, please contact [email protected].
Accreditation
John Wiley & Sons, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
John Wiley and Sons, Inc. designates this enduring material based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. For information on applicability and acceptance of continuing medical education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within 60 minutes and complete the activity during the valid credit period, which is up to three years from initial publication. Additionally, up to 3 attempts and a score of 70% or higher is needed to pass the post-test and claim credit. You will need to log into your Wiley Health Learning account (registration is free) to complete this activity and earn a certificate.
To begin, please click the Pre-test button below to contribute to our outcomes data then proceed to the course content.
